Shanbhag Vishal, Arjun N R, Chaudhuri Souvik, Pandey Akhilesh K
Department of Critical Care Medicine, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Department of Community Medicine, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Indian J Crit Care Med. 2021 Sep;25(9):987-991. doi: 10.5005/jp-journals-10071-23946.
Multiple parameters may be used to prognosticate coronavirus disease-2019 (COVID-19) patients, which are often expensive laboratory or radiological investigations. We evaluated the utility of age-adjusted Charlson comorbidity index (CCI) as a predictor of outcome in COVID-19 patients treated with remdesivir.
This was a single-center, retrospective study on 126 COVID-19 patients treated with remdesivir. The age-adjusted CCI, length of hospital stay (LOS), need for invasive mechanical ventilation (IMV), and survival were recorded.
The mean and standard deviation (SD) of age-adjusted CCI were 3.37 and 2.186, respectively. Eighty-six patients (70.5%) had age-adjusted CCI ≤4, and 36 (29.5%) had age-adjusted CCI >4. Among patients with age-adjusted CCI ≤4, 20 (23.3%) required IMV, whereas in those with age-adjusted CCI >4, 19 (52.8%) required IMV ( <0.05, Pearson's chi-square test). In those with age-adjusted CCI ≤4, the mortality was 18.6%, whereas it was 41.7% in patients with age-adjusted CCI >4 ( <0.05, Pearson's chi-square test). The receiver operating curve (ROC) of age-adjusted CCI for predicting the mortality had an area under the curve (AUC) of 0.709, = 0.001, and sensitivity 68%, specificity 62%, and 95% confidence interval (CI) [0.608, 0.810], for a cutoff score >4. The ROC for age-adjusted CCI for predicting the need for IMV had an AUC of 0.696, = 0.001, and sensitivity 67%, specificity 63%, and 95% CI [0.594, 0.797], for a cutoff score >4. ROC for age-adjusted CCI as a predictor of prolonged LOS (≥14 days) was insignificant.
In COVID-19 patients, the age-adjusted CCI is an independent predictor of the need for IMV (score >4) and mortality (score >4) but is not useful to predict LOS (CTRI/2020/11/029266).
Shanbhag V, Arjun NR, Chaudhuri S, Pandey AK. Utility of Age-adjusted Charlson Comorbidity Index as a Predictor of Need for Invasive Mechanical Ventilation, Length of Hospital Stay, and Survival in COVID-19 Patients. Indian J Crit Care Med 2021;25(9):987-991.
可使用多个参数对2019冠状病毒病(COVID-19)患者的预后进行预测,这些参数通常是昂贵的实验室或影像学检查。我们评估了年龄校正的查尔森合并症指数(CCI)作为接受瑞德西韦治疗的COVID-19患者预后预测指标的效用。
这是一项针对126例接受瑞德西韦治疗的COVID-19患者的单中心回顾性研究。记录年龄校正的CCI、住院时间(LOS)、有创机械通气(IMV)需求及生存情况。
年龄校正CCI的均值和标准差(SD)分别为3.37和2.186。86例患者(70.5%)年龄校正CCI≤4,36例(29.5%)年龄校正CCI>4。在年龄校正CCI≤4的患者中,20例(23.3%)需要IMV,而在年龄校正CCI>4的患者中,19例(52.8%)需要IMV(P<0.05,Pearson卡方检验)。在年龄校正CCI≤4的患者中,死亡率为18.6%,而在年龄校正CCI>4的患者中为41.7%(P<0.05,Pearson卡方检验)。年龄校正CCI预测死亡率的受试者工作特征曲线(ROC)曲线下面积(AUC)为0.709,P = 0.001,敏感性为68%,特异性为62%,95%置信区间(CI)为[0.608, 0.810],临界值>4。年龄校正CCI预测IMV需求的ROC曲线AUC为0.696,P = 0.001,敏感性为67%,特异性为63%,95%CI为[0.594, 0.797],临界值>4。年龄校正CCI作为延长LOS(≥14天)预测指标的ROC曲线无统计学意义。
在COVID-19患者中,年龄校正的CCI是IMV需求(评分>4)和死亡率(评分>4)的独立预测指标,但对预测LOS无用(CTRI/2020/11/029266)。
Shanbhag V, Arjun NR, Chaudhuri S, Pandey AK。年龄校正的查尔森合并症指数作为COVID-19患者有创机械通气需求、住院时间和生存预测指标的效用。《印度重症监护医学杂志》2021;25(9):987 - 991。